Manca, P., Ambrosini, M., Raimondi, A., Prisciandaro, M., Nappo, F., Tamberi, S., Fornaro, L., Giommoni, E., Spallanzani, A., Donato, S. D., Vita, F. D., Bittoni, A., Strippoli, A., Pennoni, G., Sivakumar, S., Schrock, A. B., Murgioni, S., Lonardi, S., Pietrantonio, F., Randon, G. (2026). Impact of molecular profile on switch maintenance to paclitaxel plus ramucirumab (PTX-RAM) versus continuation of first-line fluoropyrimidine and oxaliplatin (FOX) chemotherapy (ChT) in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: An exploratory endpoint of the ARMANI phase 3 randomized trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.4060